Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Apr 11;2014(4):CD007811.
doi: 10.1002/14651858.CD007811.pub2.

Sulpiride versus placebo for schizophrenia

Affiliations
Meta-Analysis

Sulpiride versus placebo for schizophrenia

Jijun Wang et al. Cochrane Database Syst Rev. .

Abstract

Background: Sulpiride is a relatively old antipsychotic drug reputed to have a low incidence of adverse effects and an effect on the negative symptoms of schizophrenia. This relatively inexpensive antipsychotic drug has a similar neuropharmacological profile to several novel atypical drugs.

Objectives: To evaluate the effects of sulpiride for schizophrenia and other similar serious mental illnesses in comparison with placebo.

Search methods: We searched the Cochrane Schizophrenia Group Trials Register (September 2008) and references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information. We updated this search 7th November 2012.

Selection criteria: We included all randomised controlled trials (RCTs) comparing sulpiride with placebo for people with schizophrenia and other types of schizophrenia-like psychoses. The primary outcome of interest was clinically significant response in global state.

Data collection and analysis: We independently inspected citations and abstracts, ordered papers, re-inspected and quality-assessed these. IMO and JW extracted data. We analysed dichotomous data using a random-effects risk ratio (RR) and estimated the 95% confidence interval (CI) around this. Where continuous data were included, we analysed these data using random-effects mean difference (MD) with a 95% CI.

Main results: No new trials were included from the 2012 search. The review still includes two trials of short duration comparing sulpiride with placebo (total n = 113). No study reported our primary outcome of interest of 'global state: clinically significant response', nor our secondary outcomes of interest of 'quality of life', 'severe adverse effects', and 'safety assessments'. As regards mental state, there were no clear differences between groups for either positive or negative symptoms; measured positive symptoms using the Manchester scale were skewed and therefore not included in meta-analysis (n = 18, 1 RCT, very low quality evidence). Measured negative symptoms using the Manchester scale also demonstrated no clear difference (n = 18, 1 RCT, MD -3.0 CI -1.66 to 1.06, very low quality evidence). Few people left these studies by three months (n = 113, 2 RCTs, RR 1.00 CI 0.25 to 4.00). One subscore finding demonstrated a significant improvement in social behaviour using the Current Behaviour Schedule (CBS) when receiving placebo (n = 18, 1 RCT, MD -2.90 CI -5.60 to -0.20). There were no data for many important outcomes such as global outcomes, service use or adverse effects.

Authors' conclusions: Sulpiride may be an effective antipsychotic drug but evidence of its superiority over placebo from randomised trials is very limited. Practice will have to use evidence from sources other than trials until better evidence is generated.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Sulpiride ‐ chemical structure
2
2
Sulpiride ‐ graphic
3
3
Study flow diagram: original 2008 search
4
4
Study flow diagram: 2012 update search
5
5
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
6
6
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
1.2
1.2. Analysis
Comparison 1 SULPIRIDE vs PLACEBO, Outcome 2 Mental state: 2a. Average score for negative symptoms (Manchester scale, negative subset, endpoint, high = poor).
1.3
1.3. Analysis
Comparison 1 SULPIRIDE vs PLACEBO, Outcome 3 Mental state: 2b. Average score for negative symptoms (SANS endpoint, endpoint, high = poor).
1.4
1.4. Analysis
Comparison 1 SULPIRIDE vs PLACEBO, Outcome 4 Behaviour: Average social behaviour score (CBS, endpoint, high = good).
1.5
1.5. Analysis
Comparison 1 SULPIRIDE vs PLACEBO, Outcome 5 Leaving the study early.

Update of

References

References to studies included in this review

Blanco 1972 {published data only}
    1. Mezquita Blanco J, Cubillo Sanchez J, Aizpiri Diaz J, Zubia Zubia B. Clinical trial with sulpiride and placebo in chronic schizophrenics study of 89 patients using the Harris‐Letemendia‐Willems scale [Ensayo clinico con Sulpiride y placebo en esquizofrenicos cronicos. Estudio de 89 enfermos, con aplicacion de la escala de Harris, Letemendia y Willems]. Archivos de Neurobiologiá ‐ Madrid 1972;35(5):453‐72. - PubMed
Soni 1990 {published and unpublished data}
    1. Soni SD, Mallik A, Schiff AA. Sulpiride in negative schizophrenia ‐ a placebo‐controlled double‐blind assessment. Human Psychopharmacology Clinical and Experimental 1990;5:233‐8.

References to studies excluded from this review

Benoit 1969 {published data only}
    1. Benoit JC, Delagrange G, Richou A, Souchon G, Sow I, Sivadon P. Contribution to the clinical study of a new neuroleptic: sulpiride [Contribution a l'etude clinique d'un nouveau neuroleptique: le sulpiride]. Semaine des Hôpitaux 1969;45(15):958‐63. - PubMed
Casey 1979 {published data only}
    1. Casey DE, Gerlach J, Simmelsgaard H. Sulpiride in tardive dyskinesia. Psychopharmacology 1979;66:73‐7. - PubMed
Gong 2001 {published data only}
    1. Gong B‐Q, Mu J‐M, Song H‐L, Song L‐X, Li D‐J. A comparison study of using clozapine in combination with sulpiride and simple using clozapine or sulpiride in treatment schizophrenia. Journal of Chinease Clinical Medicine 2001;2(6):20‐3.
Hong 1995 {published data only}
    1. Hong CW. The clinical efficacy of sulpiride in the treatment of type II schizophrenia. Chinese Journal of Neurology and Psychiatry 1995;28(3):141.
Kotler 2004 {published data only}
    1. Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment‐resistant chronic schizophrenia: evidence for improvement of mood symptomatology. International Clinical Psychopharmacology 2004;19(1):23‐6. [MEDLINE: ; MEDLINE: ] - PubMed
Liu 1996 {published data only}
    1. Liu QH, Li XL, Zhang YQ, Jin SL, Li ZC, Wang NS, et al. A control study of clozapine in combination with sulpiride in alleviating the negative symptoms of schizophrenia. Chinese Journal of Psychiatry 1996;29(2):87‐90. [CHINESE: Academic Journals]
Ma 2009 {published data only}
    1. Ma P. Tianma (gastrodia elata B1) for schizophrenia. Stanley Foundation Research Programs 2009.
Quinn 1984 {published data only}
    1. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry 1984;47(8):844‐7. - PMC - PubMed
    1. Quinn N, Marsden CD. Double blind trial of dogmatil in Huntington chorea and tardive dyskinesia [Essai en double insu du dogmatil dans la choree de huntington et la dyskinesie tardive]. Semaine des Hôpitaux 1985;61(19):1376‐80.
Sahakian 2000 {published data only}
    1. Sahakian BJ. Sulpiride effects on cognitive function in healthy volunteers. National Research Register 2000.
Schwartz 1990 {published data only}
    1. Schwartz M, Moguillansky L, Lanyi G, Sharf B. Sulpiride in tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry 1990;53(9):800‐2. [MEDLINE: ] - PMC - PubMed
Shiloh 1997 {published data only}
    1. Shiloh R, Zemishlany Z, Aizemberg D, Radwan M, Schwartz B, Dorfman‐Etrog P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double‐blind, placebo‐controlled study. British Journal of Psychiatry 1997;171:569‐73. - PubMed
Takeshita 1994 {published data only}
    1. Takeshita S, Ogura C. Effect of the dopamine D2 antagonist sulpiride on event‐related potentials and its relation to the law of initial value. International Journal of Psychophysiology 1994;16(1):99‐106. [MEDLINE: ] - PubMed
Wang 1994 {published data only}
    1. Wang CH, Qin TF, Lin YL, Zhao XF. A clinical effect and following‐up study about sulpiride and clozapine for 105 cases of the schizophrenia type ?. Journal of Xinxiang Medical College 1994;11(2):148‐51.
Wu 2005 {published data only}
    1. Wu DC, Liu YZ, Luo LX. Clinical controlled studies of olanzapine combined with sulpiride therapy in refractory schizophrenia. Chinese Journal of Behavioral Medical Science 2005;14(7):639‐41.
Wu 2006 {published data only}
    1. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose‐insulin homeostasis and lipid metabolism in first‐episode schizophrenia. Psychopharmacology 2006;186(4):572‐8. [EMBASE: 2006275796] - PubMed
Wuliji 2003 {published data only}
    1. Wuliji O. Eight week double‐blind, placebo‐controlled, randomized, trial of the traditional Mongolian medical prescription shuangzao mixture added to sulpiride in 200 patients with schizophrenia. Stanley Foundation Research Programs 2003.
Yang 2000 {published data only}
    1. Yang S, Liu G. Observation on intractable auditory hallucination treated by injecting sulpiride into acupoints. Journal of Practical Traditional Chinese Medicine 2000;16(7):24‐5.
Yao 1999 {published data only}
    1. Yao H. A double blind randomized study comparing clozapine and clozapine combination with sulpiride in the treatment of schizophrenia. Sichuan Mental Health 1999;12(4):250‐1.
Zhao 2003 {published data only}
    1. Zhao H, Zhao J, Wang Q. Comparison of sulpiride and chlorpromazine in treatment of negative psychotic symptoms with chronic schizophrenia. Health Psychology Journal 2003;11(3):224‐5.
Zhu 1999 {published data only}
    1. Zhu Y, Zhang S, Zhang D. A controlled trial comparing clomipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia. Journal of Clinical Psychological Medicine 1999;9(4):204‐5.

Additional references

Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [SUL020600] - PMC - PubMed
Andreasen 1984
    1. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa, USA: University of Iowa, 1984.
APA 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1994.
Azorin 1992
    1. Azorin JM, Dassa D, Jalfre M. The atypical neuroleptic concept [Le concept de neuroleptique atypique]. Encephale 1992;18(3):453‐7. - PubMed
Begg 1996
    1. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637‐9. - PubMed
Bland 1997
    1. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ (Clinical research ed.) 1997;315(7108):600. [PUBMED: 9302962] - PMC - PubMed
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite ]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106] - PubMed
Bratfos 1979
    1. Bratfos O, Haug JO. Comparison of sulpiride and chlorpromazine in psychoses. A double‐blind multicentre study. Acta Psychiatrica Scandinavica 1979;60:1‐9. - PubMed
Caley 1995
    1. Caley CF, Weber SS. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Annals of Pharmacotherapy 1995;2:152‐60. - PubMed
Carrere 1968
    1. Carrere J. Study of the effects of sulpiride on the mental state of 40 mental patients [Etude des effets du Sulpiride sur l'etat psychique de quarante malades mentaux]. Annales Medico Psychologiques Paris 1968;2:560‐74. - PubMed
Chisholm 2008
    1. Chisholm D, Gureje O, Saldivia S, Villalon Calderon M, Wickremasinghe R, Mendis N, et al. Schizophrenia treatment in the developing world: an interregional and multinational cost‐effectiveness analysis. Bulletin of the World Health Organization 2008;86(7):542‐51. [PUBMED: 18670667] - PMC - PubMed
Deeks 2000
    1. Deeks J. Issues in the selection for meta‐analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25‐28th. Cape Town, South Africa. 2000.
Divine 1992
    1. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9. [PUBMED: 1453246] - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21(19):2971‐80. [PUBMED: 12325113] - PubMed
Edwards 1980
    1. Edwards JG, Alexander JR, Alexander MS, Gordon A, Zutchi T. Controlled trial of sulpiride in chronic schizophrenic patients. British Journal of Psychiatry 1980;137:522‐9. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 1997;315(7109):629‐34. [PUBMED: 9310563] - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. [PUBMED: 11914310] - PubMed
Fleischhacker 2003
    1. Fleischhacker WW, Czobor P, Hummer M, Kemmler G, Kohnen R, Volavka J. Placebo or active control trials of antipsychotic drugs?. Archives of General Psychiatry 2003;60(5):458‐64. - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7‐10. - PubMed
Gerlach 1991
    1. Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia Bulletin 1991;17(2):289‐309. - PubMed
Gulliford 1999
    1. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876‐83. [PUBMED: 10221325] - PubMed
Guy 1976
    1. Guy W. Clinical Global Impression (CGI). In: Early clinical drug evaluation (ECDUE) assessment manual for psychopharmacology. Washington DC: National Institute of Mental Health, 1976.
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. [PUBMED: 12111919] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org..
Hutton 2009
    1. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27‐30. - PubMed
Hyman 2006
    1. Hyman S, Chisholm D, Kessler R, Patel V, Whiteford H. Mental disorders. Disease Control Priorities in Developing Countries. 2nd Edition. New York: Oxford University Press, 2006.
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale(PANSS) manual. North Tonawanda (NY): Multi‐Health Systems, 1986.
Kerwin 1994
    1. Kerwin RW. The new atypical antipsychotics. A lack of extrapyramidal side‐effects and new routes in schizophrenia research. British Journal of Psychiatry 1994; Vol. 164, issue 2:141‐8. [PUBMED: 7513599] - PubMed
Krawiecka 1977
    1. Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica 1977;55(4):299‐308. [PUBMED: 855676] - PubMed
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797] - PubMed
Leucht 2005b
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856] - PubMed
Leucht 2007
    1. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183‐91. [PUBMED: 16905632] - PMC - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Mason 1996
    1. Mason P, Harrison G, Glazebrook C, Medley I, Croudace T. The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISoS) coordinated by the World Health Organization. British Journal of Psychiatry 1996;169(5):580‐6. [PUBMED: 8932886] - PubMed
Mauri 1994
    1. Mauri MC, Leva P, Coppola MT, Altamura CA. L‐sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables. Progress in Neuro Psychopharmacology and Biological Psychiatry 1994;8(2):355‐6. - PubMed
Mauri 1996
    1. Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi, G. A risk‐benefit assessment of sulpiride in the treatment of schizophrenia. Drug Safety 1996;14(5):288‐98. - PubMed
Melander 2003
    1. Melander H, Ahlqvist‐Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine‐‐selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ (Clinical research ed.) 2003;326(7400):1171‐3. [PUBMED: 12775615] - PMC - PubMed
Myamoto 2003
    1. Myamoto S, Stroup TS, Duncan GE, Aoba A, Lieberman JA. Acute pharmacological treatment of schizophrenia. In: Hirsch SR, Weinberger D editor(s). Schizophrenia. Second Edition. Oxford, UK: Blackwell Publishing, 2003:442‐73.
Nishiura 1976
    1. Nishiura, M. Clinico‐pharmacological studies of sulpiride. Current Therapeutic Research 1976;20:164‐72. - PubMed
Omori 2009b
    1. Omori Ichiro M, Wang J, Soares B, Fenton M. Sulpiride versus other antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008126; CD008126] - DOI
Overall 1962
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799‐812.
Owens 1980
    1. Owens DGC, Johnstone EC. The disabilities of chronic schizophrenia: their nature and the factors contributing to their development. British Journal of Psychiatry 1980;136:384‐95. - PubMed
Patel 2007
    1. Patel V. Mental health in low‐ and middle‐income countries. British Medical Bulletin 2007;81‐82:81‐96. [PUBMED: 17470476] - PubMed
Petit 1987
    1. Petit M, Zann M, Lesieur P, Colonna L. The effect of sulpiride on negative symptoms of schizophrenia. British Journal of Psychiatry 1987;150:270‐1. - PubMed
Rathbone 2005
    1. Rathbone J, Zhang L, Zhang M, Xia J, Liu X, Yang Y. Chinese herbal medicine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003444.pub2; CD003444] - DOI - PMC - PubMed
Rezk 2012
    1. Rezk E, Mohammad HA, Refai TA, Mashoosh L. Sulpiride dose for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD009846; CD009846] - DOI
Rossler 2005
    1. Rossler W, Salize HJ, Os J, Riecher‐Rossler A. Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology 2005;15(4):399‐409. [PUBMED: 15925493] - PubMed
Rust 1989
    1. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. [PUBMED: 7823387] - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011:359‐83.
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1‐75. - PubMed
Wang 2010
    1. Wang J, Omori Ichiro M, Fenton M, Soares Bernardo GO. Sulpiride augmentation for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008125.pub2; CD008125] - DOI - PMC - PubMed
Xia 2009
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.

References to other published versions of this review

Omori 2009a
    1. Omori Ichiro M, Wang J. Sulpiride versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007811; CD007811] - DOI - PubMed
Soares 1999
    1. Soares B, Fenton M, Chue P. Sulpiride for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001162; PUBMED: 10796605] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources